Evommune, Inc. (EVMN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evommune, Inc. (EVMN) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.70 Million) by net assets ($205.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Evommune, Inc. to measure how many days the company can operate on defensive assets alone.
Evommune, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Evommune, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Evommune, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evommune, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cancom SE
F:COK
|
-0.023x |
|
Fujian SuperTech Advanced Material Co Ltd
SHG:688398
|
0.016x |
|
Xuchang Yuandong Drive Shaft Co Ltd
SHE:002406
|
0.015x |
|
Guangdong Jinma Entertainment Corp Ltd
SHE:300756
|
0.009x |
|
Navient Corp
NASDAQ:NAVI
|
0.073x |
|
Eastman Kodak Co
NYSE:KODK
|
0.024x |
|
Huayi Compressor Co Ltd
SHE:000404
|
0.032x |
|
Bassac
PA:BASS
|
-0.009x |
Annual Cash Flow Conversion Efficiency for Evommune, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of Evommune, Inc. from 2023 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Evommune, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $205.57 Million | $-76.44 Million | -0.372x | -192.17% |
| 2024-12-31 | $-144.24 Million | $-58.20 Million | 0.403x | +4.62% |
| 2023-12-31 | $-77.71 Million | $-29.97 Million | 0.386x | -- |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of … Read more